28 minutes ago

Sagimet Biosciences presented a subset analysis of the FASCINATE-2 P2 trial of denifanstat in MASH patients at The Liver Meeting showing improved fibrosis based on an AI pathology analysis method

CEO David Happel describes how this fatty acid synthase (FASN) inhibitor works, and the AI method suggesting the therapy is having an impact on liver fibrosis. Plus, plans for initiating a phase 3 study.

Recent Posts

See All

With programs using both somatic cells and iPSCs, and an NK platform for oncology in the works, Japan's Healios aims to be a leader in regenerative medicine

In a post-hoc analysis of 89bio's ENLIVEN phase 2b trial of pegozafermin presented at The Liver Meeting, data suggested that the therapy reduced progression to cirrhosis for MASH patients

An overview of Chugai, including its global ambitions and R&D capabilities, with the company’s CEO, Dr. Osamu Okuda, in Tokyo

Sagimet Biosciences presented a subset analysis of the FASCINATE-2 P2 trial of denifanstat in MASH patients at The Liver Meeting showing improved fibrosis based on an AI pathology analysis method

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight